An interventional study of 1 or 2 elastic stable intramedullary nails in Fracture, sponsored by Colaris, Joost, M.D.. Status unknown at 2 sites in Netherlands. Open to participants aged Up to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-02-26.
Sponsored by Colaris, Joost, M.D. · Not applicable, Interventional, and Treatment
The investigators created a randomized clinical trial between 1 or 2 elastic stable intramedullary nails to find out what kind of treatment is optimal for unstable both-bone midshaft forearm fractures.
Children who arrive at the emergency unit with an unstable both-bone midshaft forearm fracture will be asked to join the trial.
If the fracture will be unstable during reposition in the operating room, a randomization between 1 or 2 ESIN will be done.
The aftertreatment will be the same for both groups: above elbow plaster for 3 weeks. Outpatient clinic visits till a follow-up of 9 months. During these visits we will investigate: consolidation and dislocation on X-ray, function of both arms, complaints in daily living and complications.
2,272 studies on the registry are indexed under Fractures, Bone; 321 are open to participants now.
This study's enrollment of 60 is below the median of 68 across 1,490 interventional studies indexed under Fractures, Bone.
Browse Fractures, Bone studies →Colaris, Joost, M.D. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
pronation and supination
complications, function, esthetics, complaints in daily living, X-rays
This study is status unknown, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Colaris, Joost, M.D.